10x Genomics, Inc.

For the period ended Sep 30, 2025. Filed Nov 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 7, 2025

TXG$65.05+9.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Products and services revenue	$148,019	$151,559	$430,999	$445,554
License and royalty revenue	983	95	45,794	210
Revenue	149,002	151,654	476,793	445,764
Cost of products and services revenue	48,695	45,261	145,957	142,237
Gross profit	100,307	106,393	330,836	303,527
Operating expenses:
Research and development	57,194	66,174	182,663	197,730
Selling, general and administrative	75,355	81,704	239,517	250,517
Gain on settlement	—	—	(49,900)	—
Total operating expenses	132,549	147,878	372,280	448,247
Loss from operations	(32,242)	(41,485)	(41,444)	(144,720)
Other income (expense):
Interest income	5,199	4,971	13,156	14,422
Interest expense	3	(2)	—	(4)
Other income (expense), net	(1,165)	2,078	3,574	982
Total other income	4,037	7,047	16,730	15,400
Loss before provision for income taxes	(28,205)	(34,438)	(24,714)	(129,320)
(Benefit from) provision for income taxes	(733)	1,315	2,578	4,279
Net loss	$(27,472)	$(35,753)	$(27,292)	$(133,599)
Net loss per share, basic and diluted	$(0.22)	$(0.30)	$(0.22)	$(1.11)
Weighted-average shares used to compute net loss per share, basic and diluted	125,502,291	120,733,030	123,965,205	120,067,168

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.